Welcome to our dedicated page for IQVIA HOLDINGS SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IQVIA HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IQVIA HOLDINGS's regulatory disclosures and financial reporting.
IQVIA Holdings reported strong second‑quarter 2026 results, with revenue of $4,368 million, up 8.7% year-over-year, and segment revenue of $1,793 million in Commercial Solutions and $2,575 million in Research & Development Solutions. R&DS delivered record net new bookings of $3.15 billion, a 19% increase and a 1.22x book‑to‑bill ratio, supporting a contracted backlog of $34.2 billion.
GAAP net income was $256 million, or $1.53 diluted EPS. Adjusted EBITDA reached $994 million, up 9.2%, and Adjusted Diluted EPS was $3.15, up 12.1% year-over-year. Operating cash flow rose to $558 million and Free Cash Flow to $360 million. The company repurchased $398 million of stock in the quarter, with $2,819 million authorization remaining and a net leverage ratio of 3.59x.
On the back of this performance, IQVIA raised its full‑year 2026 guidance, now expecting revenue between $17,275 million and $17,475 million, Adjusted EBITDA between $4,000 million and $4,050 million, and Adjusted Diluted EPS between $12.80 and $13.00, reflecting a higher 6.5% revenue growth midpoint versus 5.8% previously.
IQVIA Holdings Inc. director Wims Morris Leslie received a grant of 148 deferred shares on July 14, 2026 at a reference value of $207.83 per share. Each deferred share converts into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, increasing his deferred-share holdings to 6,784. Settlement generally occurs when he ceases to be a director, upon a change in control, or upon death, and the deferred shares have no expiry date.
IQVIA Holdings Inc. reported that director Colleen A. Goggins received a grant of 183 deferred shares on July 14, 2026. Each deferred share converts into one share of common stock upon settlement when she ceases to be a director, upon a change in control, or upon death. There is no expiry date, and she now holds 5,297 deferred shares directly.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 195 deferred shares on July 14, 2026, at $207.83 per share. Each deferred share is convertible into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, when he ceases to be a director, upon a change in control, or upon death, and there is no expiry date. Following this award, Fasano holds 6,268 deferred shares directly.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl received a grant of 160 deferred shares on 2026-07-14, representing rights to an equal number of common shares upon settlement. Under the Non-Employee Director Deferral Plan, these units settle when he leaves the board, upon a change in control, or upon death. Following the award, he holds 3,289 deferred shares directly.
IQVIA Holdings Inc. reported that its wholly owned subsidiary IQVIA Inc. issued €950,000,000 of 4.625% senior notes due 2033. These unsecured notes provide long-term euro-denominated funding. Interest is payable semi-annually on June 15 and December 15, beginning December 15, 2026.
The notes mature on June 15, 2033, unless earlier repurchased or redeemed under their terms. IQVIA plans to use the net proceeds to refinance certain existing indebtedness and to pay related fees and expenses, effectively replacing older debt with this new issue.
The notes were issued under an Indenture dated June 11, 2026, among IQVIA Inc. as issuer, U.S. Bank Trust Company, National Association as trustee, and certain subsidiaries as guarantors. The issuer may redeem the notes before maturity, including a make-whole premium before June 15, 2029, and thereafter at a redemption premium that declines from 2.313% to 0%.
IQVIA Holdings Inc. announced that its subsidiary, IQVIA Inc., has priced an offering of €950,000,000 in senior notes due 2033. The notes will bear interest at 4.625% per annum, paid semi-annually on June 15 and December 15, starting December 15, 2026, and will mature on June 15, 2033 unless earlier repurchased or redeemed. IQVIA plans to use the proceeds to refinance certain existing indebtedness and to pay fees and expenses related to the transaction. The issuance is expected to close on or about June 11, 2026, subject to customary closing conditions, and the notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., plans to raise €950,000,000 through an offering of senior notes due 2033. The company expects to use the proceeds to refinance certain existing indebtedness and to pay related fees and expenses.
The notes will not be registered under the Securities Act and will be offered privately to qualified institutional buyers in the United States under Rule 144A and to non-U.S. investors under Regulation S. Completing the offering is subject to market and other customary conditions and is not yet assured.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received an award of 171 deferred shares on May 7, 2026. The grant is recorded at a reference price of $178.64 per share and increases his directly held deferred share balance to 6,636 deferred shares.
Each deferred share is convertible into one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan. The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death, and there is no expiry date on this award.
IQVIA Holdings Inc. director Colleen A. Goggins received a grant of 214 Deferred Shares on May 7, 2026, as part of her director compensation. Each deferred share is linked to one share of common stock and was valued at $178.64 per deferred share for reporting purposes.
After this grant, Goggins directly holds 5,114 Deferred Shares. These awards convert into common stock upon settlement and become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.